Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Heart Disease Epidemic: Future Cardiac Biomarker Testing May Extend To The Healthy

shcri.com - High-sensitivity troponin tests will increasingly replace previous generation assays over the next five years, and cardiac biomarker diagnostics could go beyond the typical laboratory and hospital settings to individuals with no-known history of heart disease in the future, says Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Global Analysis and Market Forecasts

According to Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Global Analysis and Market Forecasts some cardiology experts think manufacturers should invest in developing tests aimed at the normal, healthy population, with the goal of monitoring cardiac health and treating potential problems before they represent a serious threat.

Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Global Analysis and Market Forecasts says: "The sensitivity of these troponin assays are expected to reach a level where monitoring in the healthy population outside the hospital setting is a could be feasible.

"Analogous to cholesterol monitoring, one hypothesis is that troponin levels could be tracked over weeks and months, and this could potentially allow detection of low levels of myocardial injury and identification of the source."

Cardiac troponins are currently considered the gold-standard in biomarkers for the diagnosis of Acute Coronary Syndromes (ACS) and Myocardial Infarction (NYSE:MI). Typically, suspected ACS patients receive a troponin biomarker test as a matter of course. Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Global Analysis and Market Forecasts

ACS in vitro diagnostic testing has been a mainly laboratory-only process, with only a minority of hospitals presently carrying out tests at the Point-Of-Care (POC), but some interviewed experts think that it may not be long before this testing method becomes much more common thanks to anticipated improvements in POC troponin sensitivity.

However, manufacturers targeting the laboratory-based cardiac biomarker diagnostics market may face resistance from cost-conscious healthcare facilities.

"Despite the launch of improved sensitivity troponin assays, developers will find it difficult to stimulate new business in hospitals with competitor instruments, as laboratories are reluctant to replace existing instruments and brands with new ones, and are willing to wait for a high-sensitivity test to be available on their current platform," says Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Global Analysis and Market Forecasts.

Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Global Analysis and Market Forecasts forecasts the US to remain the dominant share holder in the ACS in collective in vitro diagnostic testing reagents market across the US, China, Japan, India, Brazil, the UK, Spain, France, Germany and Italy until 2018. This share is expected to slip from 81% in 2012 to 78% in 2018, due to the increasing shares of Europe and emerging markets.

Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Global Analysis and Market Forecasts provides detailed analysis of the ACS diagnostic cardiac biomarkers market.